Overview

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI
Phase:
Phase 4
Details
Lead Sponsor:
Yonsei University
Collaborator:
Daewoong Pharmaceutical Co. LTD.
Treatments:
Evolocumab
Ezetimibe
Rosuvastatin Calcium